Optimum study Ponesimod v teriflunomide

Ponesimod won decisively in this phase 2 study in RRMS. 1333 patients were randomized. Ponesimod group had lower ARR,  by 30 percent;  less combined unique active lesions (cual) by 56 percent, and less fatigue

Ofatumumab (Novartis) v. teriflunomide in 2 phase3 trials.  They had a lower ARR and time to confirmed disability. 

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Barkhof F, Kappos L, Wolinsky J.  Neurology; 2019; e1778-1786.

Authors analyzed 163 individuals from partly blinded  phase II trials of ocre and 1656 from double blind phase 3 trials for MS who underwent q 4 week scans, Control group got interferon Beta in phase 3 trials, and 1/3 also got placebo in pahse 2 trials.    Relative to placebo, ocrelizumab produced reduction in MRI activity by week 4.  Relative to interferon beta 1a, there were less ARR by week eight.